Skip to main content
Premium Trial:

Request an Annual Quote

Power3, Methodist Hospital Partner on Biomarker-Based Blood Tests for Neurodegenerative Disease

NEW YORK, July 19 (GenomeWeb News) - Power3 Medical Products and the Methodist Hospital Research Institute have partnered to search for protein biomarkers and develop a suite of tests for the diagnosis of neurodegenerative disease, Power3 said today.

 

In collaboration with Stan Appel, chair of neurology at Methodist Neurological Institute, Power3 has completed clinical validation by testing serum proteins from more than 600 patients with Lou Gehrig's, Alzheimer's, and Parkinson's disease.

 

Power3 said that it continues to evaluate serum from patients and plans to publish results from the study later this year.

The Scan

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.

Plan Rebuffed

The Associated Press reports China has rejected the World Health Organization's proposal to include the lab-leak theory in the next phase of its investigation into the origins of SARS-CoV-2.

Opossum Change

Researchers from Riken have used CRISPR to edit marsupial genomes, as Technology Review reports.